XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) Fundamental Analysis & Valuation

NASDAQ:XOMAO • US98419J4040

25.37 USD
-0.11 (-0.43%)
Last: Mar 11, 2026, 08:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This XOMAO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

5

XOMAO gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 519 industry peers in the Biotechnology industry. While XOMAO is still in line with the averages on profitability rating, there are concerns on its financial health. XOMAO is not overvalued while it is showing excellent growth. This is an interesting combination.


Dividend Valuation Growth Profitability Health

5

1. XOMAO Profitability Analysis

1.1 Basic Checks

  • XOMAO had positive earnings in the past year.
  • XOMAO had a positive operating cash flow in the past year.
  • In multiple years XOMAO reported negative net income over the last 5 years.
  • In multiple years XOMAO reported negative operating cash flow during the last 5 years.
XOMAO Yearly Net Income VS EBIT VS OCF VS FCFXOMAO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 3.75%, XOMAO belongs to the top of the industry, outperforming 89.98% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 9.14%, XOMAO belongs to the top of the industry, outperforming 92.68% of the companies in the same industry.
  • The Return On Invested Capital of XOMAO (3.31%) is better than 90.17% of its industry peers.
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROIC 3.31%
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
XOMAO Yearly ROA, ROE, ROICXOMAO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

  • XOMAO has a better Profit Margin (20.96%) than 93.83% of its industry peers.
  • The Operating Margin of XOMAO (20.92%) is better than 94.61% of its industry peers.
Industry RankSector Rank
OM 20.92%
PM (TTM) 20.96%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
XOMAO Yearly Profit, Operating, Gross MarginsXOMAO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. XOMAO Health Analysis

2.1 Basic Checks

  • XOMAO has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • Compared to 1 year ago, XOMAO has more shares outstanding
  • Compared to 5 years ago, XOMAO has more shares outstanding
  • The debt/assets ratio for XOMAO is higher compared to a year ago.
XOMAO Yearly Shares OutstandingXOMAO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
XOMAO Yearly Total Debt VS Total AssetsXOMAO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -4.56, we must say that XOMAO is in the distress zone and has some risk of bankruptcy.
  • XOMAO's Altman-Z score of -4.56 is on the low side compared to the rest of the industry. XOMAO is outperformed by 62.04% of its industry peers.
  • XOMAO has a Debt/Equity ratio of 0.87. This is a neutral value indicating XOMAO is somewhat dependend on debt financing.
  • The Debt to Equity ratio of XOMAO (0.87) is worse than 72.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Altman-Z -4.56
ROIC/WACC0.37
WACC9.06%
XOMAO Yearly LT Debt VS Equity VS FCFXOMAO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M

2.3 Liquidity

  • A Current Ratio of 3.91 indicates that XOMAO has no problem at all paying its short term obligations.
  • XOMAO has a Current ratio (3.91) which is comparable to the rest of the industry.
  • A Quick Ratio of 3.91 indicates that XOMAO has no problem at all paying its short term obligations.
  • XOMAO has a Quick ratio (3.91) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.91
Quick Ratio 3.91
XOMAO Yearly Current Assets VS Current LiabilitesXOMAO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. XOMAO Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 135.71% over the past year.
  • XOMAO shows a strong growth in Revenue. In the last year, the Revenue has grown by 103.96%.
  • XOMAO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 9.17% yearly.
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%

3.2 Future

  • Based on estimates for the next years, XOMAO will show a very strong growth in Earnings Per Share. The EPS will grow by 37.32% on average per year.
  • The Revenue is expected to grow by 40.77% on average over the next years. This is a very strong growth
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue Next Year73.27%
Revenue Next 2Y49.67%
Revenue Next 3Y33.49%
Revenue Next 5Y40.77%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
XOMAO Yearly Revenue VS EstimatesXOMAO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 100M 200M 300M
XOMAO Yearly EPS VS EstimatesXOMAO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 0 -2 -4 -6 -8 -10

More info and screens

Find the best growth stocksShow best growing peers

4

4. XOMAO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings ratio is 33.83, which means the current valuation is very expensive for XOMAO.
  • Compared to the rest of the industry, the Price/Earnings ratio of XOMAO indicates a rather cheap valuation: XOMAO is cheaper than 92.10% of the companies listed in the same industry.
  • When comparing the Price/Earnings ratio of XOMAO to the average of the S&P500 Index (26.15), we can say XOMAO is valued slightly more expensively.
  • XOMAO is valuated quite expensively with a Price/Forward Earnings ratio of 80.69.
  • 89.40% of the companies in the same industry are more expensive than XOMAO, based on the Price/Forward Earnings ratio.
  • When comparing the Price/Forward Earnings ratio of XOMAO to the average of the S&P500 Index (24.27), we can say XOMAO is valued expensively.
Industry RankSector Rank
PE 33.83
Fwd PE 80.69
XOMAO Price Earnings VS Forward Price EarningsXOMAO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • 92.49% of the companies in the same industry are more expensive than XOMAO, based on the Enterprise Value to EBITDA ratio.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 30.95
XOMAO Per share dataXOMAO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • XOMAO's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • XOMAO's earnings are expected to grow with 37.32% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y46.72%
EPS Next 3Y37.32%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. XOMAO Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 8.24%, XOMAO is a good candidate for dividend investing.
  • Compared to an average industry Dividend Yield of 1.25, XOMAO pays a better dividend. On top of this XOMAO pays more dividend than 99.42% of the companies listed in the same industry.
  • Compared to an average S&P500 Dividend Yield of 1.82, XOMAO pays a better dividend.
Industry RankSector Rank
Dividend Yield 8.24%

5.2 History

  • XOMAO has been paying a dividend for over 5 years, so it has already some track record.
  • XOMAO has not decreased its dividend in the last 3 years.
Dividend Growth(5Y)N/A
Div Incr Years0
Div Non Decr Years3
XOMAO Yearly Dividends per shareXOMAO Yearly Dividends per shareYearly Dividends per share 2021 2022 2023 2024 2025 2026 0.5 1 1.5 2

5.3 Sustainability

  • XOMAO pays out 55.43% of its income as dividend. This is a bit on the high side, but may be sustainable.
DP55.43%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
XOMAO Yearly Income VS Free CF VS DividendXOMAO Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M
XOMAO Dividend Payout.XOMAO Dividend Payout, showing the Payout Ratio.XOMAO Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

XOMAO Fundamentals: All Metrics, Ratios and Statistics

XOMA ROYALTY CORP - XOMA 8 3/8 PERP

NASDAQ:XOMAO (3/11/2026, 8:00:03 PM)

25.37

-0.11 (-0.43%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-13
Inst Owners70.51%
Inst Owner ChangeN/A
Ins Owners1.79%
Ins Owner ChangeN/A
Market Cap314.08M
Revenue(TTM)47.11M
Net Income(TTM)9.87M
Analysts81.82
Price Target66 (160.15%)
Short Float %0.04%
Short Ratio1.83
Dividend
Industry RankSector Rank
Dividend Yield 8.24%
Yearly Dividend0.47
Dividend Growth(5Y)N/A
DP55.43%
Div Incr Years0
Div Non Decr Years3
Ex-Date01-02
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)1055.58%
Min EPS beat(2)295.48%
Max EPS beat(2)1815.69%
EPS beat(4)3
Avg EPS beat(4)546.36%
Min EPS beat(4)-45.44%
Max EPS beat(4)1815.69%
EPS beat(8)4
Avg EPS beat(8)287.41%
EPS beat(12)5
Avg EPS beat(12)186.43%
EPS beat(16)6
Avg EPS beat(16)118.77%
Revenue beat(2)1
Avg Revenue beat(2)6.32%
Min Revenue beat(2)-20.06%
Max Revenue beat(2)32.7%
Revenue beat(4)2
Avg Revenue beat(4)32.77%
Min Revenue beat(4)-20.06%
Max Revenue beat(4)120.82%
Revenue beat(8)5
Avg Revenue beat(8)16.19%
Revenue beat(12)7
Avg Revenue beat(12)15.39%
Revenue beat(16)8
Avg Revenue beat(16)0.85%
PT rev (1m)4.5%
PT rev (3m)12.97%
EPS NQ rev (1m)0%
EPS NQ rev (3m)11.76%
EPS NY rev (1m)0%
EPS NY rev (3m)7.67%
Revenue NQ rev (1m)-0.72%
Revenue NQ rev (3m)-0.46%
Revenue NY rev (1m)-0.2%
Revenue NY rev (3m)-0.17%
Valuation
Industry RankSector Rank
PE 33.83
Fwd PE 80.69
P/S 6.67
P/FCF N/A
P/OCF 57.43
P/B 2.91
P/tB 4.95
EV/EBITDA 30.95
EPS(TTM)0.75
EY2.96%
EPS(NY)0.31
Fwd EY1.24%
FCF(TTM)-1.19
FCFYN/A
OCF(TTM)0.44
OCFY1.74%
SpS3.81
BVpS8.72
TBVpS5.12
PEG (NY)0.21
PEG (5Y)N/A
Graham Number12.13
Profitability
Industry RankSector Rank
ROA 3.75%
ROE 9.14%
ROCE 4.2%
ROIC 3.31%
ROICexc 4.14%
ROICexgc 5.42%
OM 20.92%
PM (TTM) 20.96%
GM N/A
FCFM N/A
ROA(3y)-14.85%
ROA(5y)-6.52%
ROE(3y)-31.32%
ROE(5y)-15.58%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.18
Health
Industry RankSector Rank
Debt/Equity 0.87
Debt/FCF N/A
Debt/EBITDA 7.77
Cap/Depr 880.03%
Cap/Sales 42.84%
Interest Coverage 0.83
Cash Conversion 45.03%
Profit Quality N/A
Current Ratio 3.91
Quick Ratio 3.91
Altman-Z -4.56
F-Score6
WACC9.06%
ROIC/WACC0.37
Cap/Depr(3y)7738.51%
Cap/Depr(5y)4653.1%
Cap/Sales(3y)108.05%
Cap/Sales(5y)64.84%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)135.71%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%144.03%
EPS Next Y157.93%
EPS Next 2Y46.72%
EPS Next 3Y37.32%
EPS Next 5YN/A
Revenue 1Y (TTM)103.96%
Revenue growth 3Y-9.28%
Revenue growth 5Y9.17%
Sales Q2Q%29.93%
Revenue Next Year73.27%
Revenue Next 2Y49.67%
Revenue Next 3Y33.49%
Revenue Next 5Y40.77%
EBIT growth 1Y152.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year144.59%
EBIT Next 3Y48.37%
EBIT Next 5YN/A
FCF growth 1Y55.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y130.18%
OCF growth 3YN/A
OCF growth 5YN/A

XOMA ROYALTY CORP - XOMA 8 3/8 PERP / XOMAO FAQ

What is the ChartMill fundamental rating of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

ChartMill assigns a fundamental rating of 5 / 10 to XOMAO.


What is the valuation status for XOMAO stock?

ChartMill assigns a valuation rating of 4 / 10 to XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO). This can be considered as Fairly Valued.


Can you provide the profitability details for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?

XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) has a profitability rating of 5 / 10.


What are the PE and PB ratios of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) stock?

The Price/Earnings (PE) ratio for XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is 33.83 and the Price/Book (PB) ratio is 2.91.


What is the earnings growth outlook for XOMA ROYALTY CORP - XOMA 8 3/8 PERP?

The Earnings per Share (EPS) of XOMA ROYALTY CORP - XOMA 8 3/8 PERP (XOMAO) is expected to grow by 157.93% in the next year.